Selecting a plant in-vitro production platform is often treated as a practical comparison among biomass growth, metabolite titre, transformability, and scale. That framing is incomplete when specialized-metabolite biosynthesis depends on differentiated cell identity, intercellular pathway partitioning, tissue-specific transport, or developmentally regulated competence. This original comparative decision article evaluates callus, suspension cells, hairy roots, and regenerated plants as biologically distinct production states rather than interchangeable culture formats. The analysis integrates evidence on cell-type-specific specialized metabolism, multicellular compartmentation, tissue culture, metabolic engineering, regeneration, and spatial metabolomics. The central argument is that platform selection should begin with the biological requirements of the target pathway and only then consider process convenience. Callus and suspension cultures can provide accessibility, rapid manipulation, and scalable cell-based processing, yet dedifferentiation may alter regulatory or spatial features required by some pathways. Hairy roots retain root-like organization and high genetic accessibility, but transformation itself can modify metabolic state. Regenerated plants can restore broader tissue context, although regeneration does not guarantee chemical fidelity or process efficiency. We therefore propose a conditional decision architecture that separates biosynthetic compatibility, spatial-pathway requirements, manipulation, stability, and scale instead of collapsing them into a single platform ranking. The framework also identifies cases in which parallel or staged use of more than one platform is more defensible than premature commitment. Its principal limitation is that current evidence remains strongly species-, pathway-, and protocol-dependent; prospective matched cross-platform validation is still required.
